Risankizumab, guselkumab, and ustekinumab were associated with the lowest risk for progression from psoriasis to psoriatic arthritis.

Phase 3 studies showed zasocitinib, a highly selective oral tyrosine kinase 2 inhibitor, provided rapid, durable skin improvement.

Deucravacitinib showed strong psoriasis control and rapid scalp clearance with mild adverse events in real-world practice.

UCB, a global biopharmaceutical company, today announced new data in moderate-to-severe plaque psoriasis (PSO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, March 27–31.

In a significant policy shift aimed at strengthening national security and curbing the proliferation of what officials describe as "liberalized" private militias, the Uganda Police Force (UPF) has ...

Arkansas Children’s has appointed Alison Ziari, M.D., M.S., as senior vice president of the Arkansas Children’s Practice Plan and ...

Most State-Owned Enterprises (SOEs) have a dual mandate, commercially inclined and simultaneously mandated to run programmes ...

TEHRAN, Iran (AP) - Iran, the United States and Israel reached a two-week ceasefire Wednesday as U.S. President Donald Trump pulled back from his threats to destroy Iranian civilization.

On Saturday, June 6, 2026, the Visual Arts Center of New Jersey will celebrate its spring exhibitions with a Community Day ...

Glasgow-headquartered Holmes Miller has appointed Matt Pearson as studio lead for its Leeds office following a growth in ...

ISLAMABAD: Pakistan State Oil (PSO) and Oman Trading International are engaged in constructive discussions to explore the possibility of providing additional oil cargoes to help Pakistan meet energy ...